HBOT Applications

UHMS-Approved Level B

Idiopathic Sudden Sensorineural Hearing Loss

FDA-approved adjunctive treatment (2011) when corticosteroid therapy fails. Reverses cochlear hypoxia and reduces endolymphatic hydrops, improving hearing recovery rates.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

90 min

Sessions

10 – 20

Frequency

Once daily, 5×/week

Evidence basis: UHMS / FDA-Approved

References: 9 20

Investigational / Preclinical Level C

Tinnitus

Investigational use for chronic tinnitus associated with cochlear hypoxia. Some clinical studies show improvement in tinnitus severity scores. However, a Cochrane review found no evidence of benefit for chronic tinnitus and does not recommend HBOT for this purpose.